Statistics for A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease
Total visits
| views | |
|---|---|
| A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease | 67 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 1 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:34f32215-8f84-4d6f-9ccf-bc70da8d055d | 55 |
| sfaa232.pdf | 45 |
| java.util.UUID:81880f1f-8260-4693-8afc-2602f1731424 | 24 |
| java.util.UUID:24293544-5c0b-47f9-9134-19b9b3ff3b4f | 9 |
| java.util.UUID:c5e1a100-686d-44b3-ae4a-7c92b6522112 | 2 |
Top country views
| views | |
|---|---|
| United States | 54 |
| China | 1 |
| Germany | 1 |
| United Kingdom | 1 |
| Japan | 1 |
| South Korea | 1 |
| Malaysia | 1 |
| Turkey | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 41 |
| Anaheim | 3 |
| White Plains | 2 |
| Ann Arbor | 1 |
| Baltimore | 1 |
| Beijing | 1 |
| Cambridge | 1 |
| Gunzenhausen | 1 |
| Indianapolis | 1 |
| Istanbul | 1 |
| Richmond | 1 |
| Seremban | 1 |
| Tustin | 1 |